Trials / Recruiting
RecruitingNCT06575075
Pilot Study of RR-HNK in OCD
A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Carolyn Rodriguez · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Detailed description
This protocol examines the safety and efficacy of 2 dosage levels of intravenous RR-HNK administration in individuals with OCD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RR-HNK/Hydroxynorketamine | (2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist. |
| DRUG | Placebo | Sterile Saline |
Timeline
- Start date
- 2026-01-23
- Primary completion
- 2028-11-30
- Completion
- 2029-11-30
- First posted
- 2024-08-28
- Last updated
- 2026-03-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06575075. Inclusion in this directory is not an endorsement.